Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever.

ABSTRACT:

Objectives

There is no consensus on canakinumab treatment tapering and discontinuation strategies in colchicine-resistant FMF patients. In this study, we aimed to establish a treatment management and discontinuation protocol in paediatric FMF patients treated with canakinumab.

Methods

Fifty-eight FMF patients treated with canakinumab were included. Since 2020, we have applied a protocol based on our experience whereby canakinumab is administered monthly in the first 6 months, followed by bimonthly for 6 months, and a final period of every 3 months (for 6 months). The patients were divided into two groups: 2012-2019 (group A) and 2020-2022 (group B).

Results

In group A (n = 33), the median duration of canakinumab treatment was 2.5 years [interquartile range (IQR) 1.9-3

SUBMITTER: Sener S 

PROVIDER: S-EPMC10629778 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature